Liver Transplantation

Introduction Ischemia–reperfusion injury (IRI) remains a major barrier in organ transplantation and contributes significantly to graft dysfunction, early allograft injury and organ discard. Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, has recently emerged as a key mechanism underlying tissue injury during ischemia and reperfusion.

Problem Statement Despite increasing recognition of ferroptosis in transplant-associated injury, no clinically applicable therapies currently target this pathway. Existing ferroptosis inhibitors have been limited by poor pharmacokinetics and inadequate translational potential, while the precise temporal dynamics of lipid peroxidation during human transplantation remain incompletely characterized.

Summary This landmark translational study identifies ferroptosis as a major therapeutic target in transplantation and introduces FXT-001 as a first-in-class drug-like ferroptosis inhibitor with promising clinical applicability. The investigators demonstrated that lipid peroxidation rapidly peaks within the first hour after graft reperfusion in human liver transplantation and correlates with severe ischemia–reperfusion injury. FXT-001 combines radical-trapping antioxidant activity with iron-binding capacity, enabling dual suppression of lipid peroxidation and ferroptotic cell death. Mechanistic studies showed preferential localization of FXT-001 within mitochondria and endolysosomal compartments, where it modulates subcellular iron handling and prevents membrane lipid radical propagation. In clinically relevant porcine liver donation-after-circulatory-death models, FXT-001 significantly reduced hepatocellular injury markers, improved glucose metabolism and preserved choleretic function during ex situ reperfusion. Parallel experiments in porcine and declined human donor lungs demonstrated reduced edema formation, lower extravascular lung water and improved graft compliance following ferroptosis inhibition. Importantly, the study also developed next-generation analogues, FXT-002 and FXT-003, with improved pharmacokinetic and safety profiles while retaining potent ferroptosis inhibition. The findings position ferroptosis inhibition as a potentially transformative strategy not only in transplantation but also across a broad spectrum of ischemia-associated conditions including myocardial infarction, stroke and vascular surgery. Overall, this work provides one of the strongest translational demonstrations to date that pharmacologic ferroptosis blockade can meaningfully improve organ preservation and graft function in human-relevant systems.

Introduction Colorectal liver metastases remain a major cause of cancer-related mortality, and curative treatment is traditionally limited to patients eligible for hepatic resection. However, many patients present with technically unresectable liver-only disease despite favorable tumor biology and good response to systemic chemotherapy. In recent years, liver transplantation has re-emerged as a potential treatment strategy for carefully selected patients with unresectable colorectal liver metastases.

Problem Statement Although promising survival outcomes have been reported with liver transplantation in selected metastatic colorectal cancer patients, widespread adoption remains limited by donor organ scarcity, concerns regarding recurrence and uncertainty regarding long-term oncologic benefit compared with modern systemic therapy alone.

Summary This study demonstrates that liver transplantation using a living-donor RAPID approach provides a substantial survival advantage over chemotherapy alone in carefully selected patients with unresectable colorectal liver metastases. Eligible patients had liver-confined disease with stable disease or tumor regression following systemic therapy, reflecting strict biologic selection criteria. Patients undergoing transplantation achieved markedly superior long-term survival compared with patients who could not proceed because of donor unavailability, supporting transplantation as a potentially curative strategy in highly selected metastatic colorectal cancer. The RAPID technique, involving staged partial liver transplantation with delayed hepatectomy, also highlights an innovative approach to expanding transplant feasibility while minimizing donor burden. Although recurrence remained common after transplantation, recurrent disease was often compatible with prolonged post-recurrence survival, suggesting that transplantation may meaningfully alter disease trajectory even when recurrence occurs. Importantly, the study reinforces the growing concept that tumor biology and treatment responsiveness may be more relevant than traditional metastatic classification alone when considering advanced surgical or transplant-based oncologic strategies. Overall, these findings strengthen the evolving role of liver transplantation in transplant oncology and support living-donor transplantation as a feasible pathway to expand access for selected patients with unresectable colorectal liver metastases.